Literature DB >> 9572998

Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia.

G Barosi1, A Ambrosetti, A Centra, A Falcone, C Finelli, P Foa, A Grossi, R Guarnone, S Rupoli, L Luciano, M C Petti, E Pogliani, D Russo, M Ruggeri, S Quaglini.   

Abstract

An unexpectedly high incidence of blast transformation after splenectomy has been reported in patients with myelofibrosis with myeloid metaplasia. However, whether this was associated with spleen removal after adjustment for risk factors was not determined. We conducted a multicenter historical cohort study of patients with myelofibrosis with myeloid metaplasia diagnosed from January 1970 through January 1994. A total of 549 patients (325 men and 224 women from 22 to 92 years of age; median age, 63 years) were included in the final data set. The Cox's proportional-hazards model was used to identify factors associated with blast transformation and death. To further adjust for factors related to spleen removal assignment, a propensity score for splenectomy was estimated using recursive-partitioning analysis. Blast transformation developed in 78 patients (14.2%). Patients who underwent splenectomy developed more blast transformations than those who were not splenectomized (23 of 87 [26.4%] v 55 of 462 [11.9%]; P < .001). The cumulative incidence of blast transformation 12 years after diagnosis was 27.0% in nonsplenectomized patients and 55.0% in splenectomized ones (P = . 01). The risk factors independently predictive of blast transformation included prior splenectomy (relative risk = 2.61), platelet count less than 100 x 10(9)/L at diagnosis (relative risk = 2.45), and the presence of blasts in peripheral blood at diagnosis (relative risk = 2.31). The relative risk of blast transformation in splenectomized patients increased from 2.2 at 48 months from diagnosis to 14.3 at 12 years. Patients with the same propensity score for splenectomy showed a higher risk for blast transformation on the basis of having undergone splenectomy (P = .02). In conclusion, the risk of blast transformation is significantly increased in subjects who underwent splenectomy and appears to be independent of factors related to spleen removal assignment.

Entities:  

Mesh:

Year:  1998        PMID: 9572998

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

Review 2.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

3.  Evaluating uses of data mining techniques in propensity score estimation: a simulation study.

Authors:  Soko Setoguchi; Sebastian Schneeweiss; M Alan Brookhart; Robert J Glynn; E Francis Cook
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-06       Impact factor: 2.890

Review 4.  Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.

Authors:  Aravind Ramakrishnan; Brenda M Sandmaier
Journal:  Expert Rev Hematol       Date:  2010-02-01       Impact factor: 2.929

5.  Spleens of myelofibrosis patients contain malignant hematopoietic stem cells.

Authors:  Xiaoli Wang; Sonam Prakash; Min Lu; Joseph Tripodi; Fei Ye; Vesna Najfeld; Yan Li; Myron Schwartz; Rona Weinberg; Paul Roda; Attilio Orazi; Ronald Hoffman
Journal:  J Clin Invest       Date:  2012-11       Impact factor: 14.808

Review 6.  Leukemia secondary to myeloproliferative neoplasms.

Authors:  Andrew J Dunbar; Raajit K Rampal; Ross Levine
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

Review 7.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.

Authors:  M C Le Bousse-Kerdilès; M C Martyré
Journal:  Springer Semin Immunopathol       Date:  1999

8.  Primary myelofibrosis terminated in basophilic leukemia and successful allogeneic bone marrow transplantation.

Authors:  Naoshi Sugimoto; Takayuki Ishikawa; Saori Gotoh; Isaku Shinzato; Akiko Matsushita; Kenichi Nagai; Noriko Ohgoh; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

Review 9.  Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.

Authors:  Bing Li; John O Mascarenhas; Raajit K Rampal
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

10.  Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.

Authors:  Fabio P S Santos; Constantine S Tam; Hagop Kantarjian; Jorge Cortes; Deborah Thomas; Raphael Pollock; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.